Microbial Community Composition and Metabolism in Cystic Fibrosis
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Scientist have begun to realize that many types of bacteria often live together as a complex community, and the investigators wish to apply that idea to the bacteria in the respiratory system of people with Cystic Fibrosis (CF). It is possible that the survival of the many millions of bacteria in the CF lung depends on the production of special chemicals that might be made only by very few types of bacteria. If that is true, medicines that interfere with those chemicals could treat the lung infections that cause trouble for nearly all people with CF. The investigators wish to study the production of several potentially critical chemicals by the respiratory bacteria and to examine the effect of those chemicals on the makeup of the entire community of bacteria. To detect all the bacteria in that community, the investigators will use new methods that use bacterial genetic information and can detect hundreds of different types of bacteria in respiratory samples of individual CF patients.
| Condition |
|---|
|
Cystic Fibrosis |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Respiratory Microbial Community Composition and Metabolism in Cystic Fibrosis |
throat swabs or sputum
| Estimated Enrollment: | 120 |
| Study Start Date: | August 2009 |
| Groups/Cohorts |
|---|
| Cystic Fibrosis patient during outpatient clinic visit |
| Cystic Fibrosis patients during hospitalization |
| CF patients about to have sinus surgery and bronchoscopy |
Eligibility| Ages Eligible for Study: | 2 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Cystic fibrosis patients will be contacted during clinical care visits and inpatient hospitalizations.
Inclusion Criteria:
- confirmed diagnosis of Cystic Fibrosis
- 2 to 55 years of age
Exclusion Criteria:
- None
Contacts and Locations| United States, Massachusetts | |
| Children's Hosptital, Boston | Recruiting |
| Boston, Massachusetts, United States, 02115 | |
| Contact: Magen Lorenzi 617-335-6077 magen.lorenzi@childrens.harvard.edu | |
| Contact: Thomas Martin, MD 617-355-8754 thomas.martin@childrens.harvard.edu | |
More Information
No publications provided
| Responsible Party: | Thomas Martin, MD, Children's Hospital, Boston |
| ClinicalTrials.gov Identifier: | NCT00954018 History of Changes |
| Other Study ID Numbers: | 09-04-018 |
| Study First Received: | August 5, 2009 |
| Last Updated: | August 5, 2009 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Cystic Fibrosis Fibrosis Pancreatic Diseases Digestive System Diseases Lung Diseases |
Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on May 19, 2013